Loading
Liver cancer growing into the main vein that brings blood from the gut to the liver. It marks advanced disease, rules out most surgery and transplant, and makes some local treatments unsafe.
Hepatocellular carcinoma has a propensity to invade the portal and hepatic veins; macrovascular invasion defines BCLC stage C, excludes transplantation and usually resection, and makes TACE hazardous because the liver would lose both blood supplies, so radioembolisation, radiotherapy to the thrombus or systemic therapy (atezolizumab-bevacizumab) are used. Portal hypertension from cirrhosis, separately, causes varices and ascites and limits treatment options. Renal cell carcinoma can similarly extend into the renal vein and inferior vena cava, which is removed with the kidney.
Hepatocellular carcinoma grows in a cirrhotic liver and spreads first inside it and into the portal vein, so staging depends on liver function and vascular invasion as much as on size.
Same organ: Early hepatocellular carcinoma (BCLC 0 and A), Intermediate hepatocellular carcinoma (BCLC B), Advanced hepatocellular carcinoma (BCLC C), Hepatoblastoma
Showing the organ this term concerns: Hepatocellular carcinoma.
Shares TARE / SIRT (radioembolisation with yttrium-90), BCLC staging, Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
Shares Cirrhosis, BCLC staging, Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Cirrhosis, BCLC staging, Advanced hepatocellular carcinoma (BCLC C).
Shares BCLC staging, Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
Shares BCLC staging, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Renal cell carcinoma, Hepatocellular carcinoma.
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.